TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

Completed · Phase 3

Conditions studied: Heart Failure

In brief

TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over 12 months in patients with heart failure who are hospitalized.

Key facts

Study ID

NCT03296813

Run by

Duke University

People needed

2973

Starts

2018-07-11

Expected to finish

2022-07-29

Last updated by the study team

2025-10-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient hospitalized (≥ 24 hours or over a change in calendar date) with worsening of chronic heart failure, or new diagnosis of heart failure AND meets one of the following criteria:
• Has a left ventricular ejection fraction (EF) ≤40% within 24 months prior to and including index hospitalization by any method (with most recent value used to determine eligibility)
• Has an elevated natriuretic peptide level (either NT-pro-B-type natriuretic peptide or B-type natriuretic peptide) during index hospitalization as measured by local laboratory (with most recent value used to determine eligibility)
• Plan for a daily outpatient oral loop diuretic regimen upon hospital discharge with anticipated need for long-term loop diuretic use
• ≥ 18 years of age
• Signed informed consent

You may not qualify if…

• End-stage renal disease requiring renal replacement therapy
• Inability or unwillingness to comply with the study requirements
• History of heart transplant or actively listed for heart transplant
• Implanted left ventricular assist device or implant anticipated <3 months
• Pregnant or nursing women
• Malignancy or other non-cardiac condition limiting life expectancy to <12 months
• Known hypersensitivity to furosemide, torsemide, or related agents

Where it is running

• The Heart Center, PC — Huntsville, Alabama, United States
• University of Arizona — Tucson, Arizona, United States
• V.A. Greater Los Angeles Healthcare System — Los Angeles, California, United States
• Kaiser Permanente Medical Center — San Francisco, California, United States
• Saint Francis Hospital and Medical Center — Hartford, Connecticut, United States
• Yale — New Haven, Connecticut, United States
• West Haven VA Medical Center — West Haven, Connecticut, United States
• Holy Cross Hospital — Fort Lauderdale, Florida, United States
• University of Florida - Gainesville — Gainesville, Florida, United States
• Emory Health Care — Atlanta, Georgia, United States
• Augusta University — Augusta, Georgia, United States
• Queens Medical Center — Honolulu, Hawaii, United States
• Fox Valley Clinical Research Center — Aurora, Illinois, United States
• Northwestern Memorial Hospital — Chicago, Illinois, United States
• University of Chicago — Chicago, Illinois, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Methodist Medical Center of Illinois — Peoria, Illinois, United States
• Indiana University Health Bloomington Hospital — Bloomington, Indiana, United States
• Indiana University Medical Center — Indianapolis, Indiana, United States
• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
• University Medical Center — New Orleans, Louisiana, United States
• Oschner Clinic — New Orleans, Louisiana, United States
• VA Medical Center/University of Maryland — Baltimore, Maryland, United States
• Shady Grove Medical Center — Rockville, Maryland, United States
• Russel Medical Center — Alexander City, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.